




Licensing Opportunity

Improved coronary collateral artery growth by inhibition of INF-beta

Market sector(s): Cardiovascular disease.

Summary: Targets for improving coronary collateral artery growth (arteriogenesis) were identified by microarray comparison of gene expression levels in stimulated monocytes from patients with good vs. bad growth of collateral arteries after suffering from arterial obstruction. One of the most interesting targets was found to be interferon-beta: patients with adequate collateral development are characterized by a downregulated interferon pathway as compared to patients with poor collateralization. IFN-beta receptor KO mice were shown to improve perfusion in an established hindlimb model. We are actively looking for partners to develop antibodies against INF-beta as well as ligands for blocking of the INF-beta receptor.



Nature Reviews | Drug Discovery

Nature Reviews Drug Discovery 2, 863-872

Patent status: Patent application filed in August 2007 (priority phase).

R&D Status: Positive effect of inhibiting INF-beta shown in mice.

More information: available on request.